PROMETHERA BIOSCIENCES
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
PROMETHERA BIOSCIENCES
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2009-01-01
Address:
Mont-saint-guibert, Brabant Wallon, Belgium
Country:
Belgium
Website Url:
http://www.promethera.com
Total Employee:
101+
Status:
Active
Contact:
32 1 039 43 00
Email Addresses:
[email protected]
Total Funding:
149.1 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Vimeo GlobalSign Domain Verification Vimeo CDN DocuSign Symantec.cloud Exclaimer Equinix
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-04-10 | Baliopharm | Baliopharm acquired by Promethera Biosciences | N/A |
Investors List
Pegasus Tech Ventures
Pegasus Tech Ventures investment in Series D - Promethera Biosciences
Sony Innovation Fund
Sony Innovation Fund investment in Series D - Promethera Biosciences
ITOCHU Technology Ventures
ITOCHU Technology Ventures investment in Series D - Promethera Biosciences
Sansei Capital Investment
Sansei Capital Investment investment in Series D - Promethera Biosciences
Shibuya Kogyo
Shibuya Kogyo investment in Convertible Note - Promethera Biosciences
Shinsei Corporate Investment
Shinsei Corporate Investment investment in Convertible Note - Promethera Biosciences
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series C - Promethera Biosciences
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series C - Promethera Biosciences
Fund+
Fund+ investment in Series C - Promethera Biosciences
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Series C - Promethera Biosciences
Key Employee Changes
| Date | New article |
|---|---|
| 2019-12-11 | Prometheus Bio Taps Thierry Dervieux as Chief Development Officer |
Official Site Inspections
http://www.promethera.com
- Host name: 217.19.237.54.static.hosted.by.combell.com
- IP address: 217.19.237.54
- Location: Brussels Belgium
- Latitude: 50.8336
- Longitude: 4.3337
- Timezone: Europe/Brussels
- Postal: 1060
